Functionalized nanoparticles for real time imaging of cerebral lesions

用于脑损伤实时成像的功能化纳米颗粒

• 批准号: 350345-2007
• 负责人: Maysinger, Dusica
• 金额: $ 9.73万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Strategic Projects - Group
• 财政年份: 2008
• 资助国家: 加拿大
• 起止时间: 2008-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=402033
• 关键词: Functionalized; nanoparticles; real; time; imaging

Stroke victims commonly suffer micro-ischemic lesions of the brain that initially remain unnoticed due to their small size. In the long term, however, they tend to trigger irreversible neurodegenerative changes accompanied by debilitating complications for which no cure has been found. We propose here to develop new real time non-invasive imaging protocols using luminescent nanoparticles or X-ray computed tomography (CT) contrast agents. Our approach is unique in as much as it relies on the synergy of (i) materials nanoscience for the design and synthesis of imaging agents, (ii) mechanistic pharmacology for the deployment of imaging and pre-clinical studies and (iii) state-of-the-art medical imaging technology, which will be provided by instrumentation designed and commercialized by the Canadian-based company ART Advanced Research Technologies Inc. The overall objectives are: 1. to develop and test novel near IR emitting quantum dots and X-Ray tomography contrast agents suitable for real time, non-invasive 1 imaging; 2. to use these imaging tools to assess the extent of ischemic lesions in rodent stroke models; and 3. to test the effectiveness of new intranasal formulations of either NAD+ (Nicotinamide adenine dinucleotide), a drug in clinical use clinically, and of a drug "cocktail", composed of minocycline, riluzole and nimodipine, used in pre-clinical investigations. While the research proposed is aimed towards preclinical screening methods for drugs in the treatment of ischemic lesions, the imaging devices and agents developed will be widely applicable in pre-clinical research and benefit the Canadian health community by providing fast, sensitive, and reliable methods in drug development and diagnostics

中风患者通常遭受大脑的微缺血性病变，最初由于其体积小而未被注意到。然而，从长远来看，它们往往会引发不可逆的神经退行性变化，伴随着衰弱的并发症，没有治愈已经found. We建议在这里开发新的真实的时间非侵入性成像协议使用发光纳米粒子或X射线计算机断层扫描（CT）造影剂。我们的方法是独一无二的，因为它依赖于（i）用于成像剂设计和合成的材料纳米科学，（ii）用于成像和临床前研究部署的机械药理学，以及（iii）最先进的医学成像技术，这将由位于亚特兰大的公司ART Advanced Research Technologies Inc.设计和商业化的仪器提供。总体目标是：1.开发和测试新的近红外发射量子点和X射线断层造影剂，适用于真实的时间，非侵入性1成像; 2.使用这些成像工具来评估啮齿动物中风模型中缺血性病变的程度;以及3.测试NAD+（烟酰胺腺嘌呤二核苷酸）（一种临床上使用的药物）和药物“鸡尾酒”（由米诺环素、利鲁唑和尼莫地平组成）（用于临床前研究）的新鼻内制剂的有效性。虽然拟议的研究旨在为治疗缺血性病变的药物提供临床前筛选方法，但开发的成像设备和试剂将广泛适用于临床前研究，并通过提供快速，灵敏和可靠的药物开发和诊断方法使加拿大卫生界受益